Praveena Kandula

Praveena Kandula is a Partner at Aditum Bio, a specialized biotechnology venture capital firm, and she is currently based in Oakland, California. In this senior investment role, she actively manages a portfolio of biotechnology assets and evaluates promising drug candidates to accelerate clinical development timelines. Kandula collaborates closely with notable industry professionals, including Aditum Bio Co-Founder Mark Fishman and Operating Partner Chris Klee, to build independent portfolio companies around specific therapeutic mechanisms. Her primary investment scope includes in-licensing early-stage drug candidates and spinning out specialized startups, operating through specific investment vehicles such as Aditum Bio Fund 1 LP, GP 1 LLC, and GP 2 LLC. Ultimately, Kandula's current professional focus centers on financing advanced research and development initiatives that target complex disease mechanisms across both large and highly targeted patient populations.